Marcotte Richard, Sayad Azin, Brown Kevin R, Sanchez-Garcia Felix, Reimand Jüri, Haider Maliha, Virtanen Carl, Bradner James E, Bader Gary D, Mills Gordon B, Pe'er Dana, Moffat Jason, Neel Benjamin G
Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.
The Donnelly Centre, University of Toronto, ON M5S 3E1, Canada.
Cell. 2016 Jan 14;164(1-2):293-309. doi: 10.1016/j.cell.2015.11.062.
Large-scale genomic studies have identified multiple somatic aberrations in breast cancer, including copy number alterations and point mutations. Still, identifying causal variants and emergent vulnerabilities that arise as a consequence of genetic alterations remain major challenges. We performed whole-genome small hairpin RNA (shRNA) "dropout screens" on 77 breast cancer cell lines. Using a hierarchical linear regression algorithm to score our screen results and integrate them with accompanying detailed genetic and proteomic information, we identify vulnerabilities in breast cancer, including candidate "drivers," and reveal general functional genomic properties of cancer cells. Comparisons of gene essentiality with drug sensitivity data suggest potential resistance mechanisms, effects of existing anti-cancer drugs, and opportunities for combination therapy. Finally, we demonstrate the utility of this large dataset by identifying BRD4 as a potential target in luminal breast cancer and PIK3CA mutations as a resistance determinant for BET-inhibitors.
大规模基因组研究已在乳腺癌中鉴定出多种体细胞畸变,包括拷贝数改变和点突变。然而,识别由基因改变导致的因果变异和新出现的脆弱性仍然是重大挑战。我们对77个乳腺癌细胞系进行了全基因组小发夹RNA(shRNA)“敲除筛选”。使用分层线性回归算法对筛选结果进行评分,并将其与附带的详细遗传和蛋白质组学信息整合,我们识别出乳腺癌中的脆弱性,包括候选“驱动因素”,并揭示癌细胞的一般功能基因组特性。基因必需性与药物敏感性数据的比较表明了潜在的耐药机制、现有抗癌药物的作用以及联合治疗的机会。最后,我们通过将BRD4鉴定为管腔型乳腺癌的潜在靶点以及将PIK3CA突变鉴定为BET抑制剂的耐药决定因素,证明了这个大型数据集的实用性。